Our Vision
• “To revolutionise the way the best drugs can be selected during their discovery and validation”
• “To produce better data, faster, more economically and with less failures”
• “To maximise outcomes from using patient-derived, predictive models of disease”
• “To expedite functional precision medicine in the clinic”
We Can:
Support
Offer you a full consultation service to identify the best service for you
Advice
Help you design and perform the most physiologically relevant experiments using state-of-the-art technology
Add Value
Assist you in deciding what are the best-endpoints to your scientific or clinical question
Collaborate
Provide anything from a one-off consultation to running all experiments in our dedicated facility
UpScale3D Technology
We offer a robust, customisable, cost-efficient and medium-throughput 3D ex vivo assay service, which makes it possible to move away from the “one therapy fits all” approach and opens doors for precision medicine to tailor peoples’ individual treatment needs. The novel characteristics of our technology enable rapid decision making to prioritize the most promising drug candidates, biomarkers and drug combination strategies for preclinical drug discovery and development.
Large Throughput
Our microfluidic technology provides a data throughput up to 100 times larger than standard ultra-low-adhesion (ULA) plates for the same starting material. This enables a high number of replicates for your conditions of interest even when dealing with very small patient-derived samples, resulting in greater statistical significance and data that gives you confidence about drug efficacy.
Relevant Models
The disease microenvironment (e.g. tumour microenvironment-TME) affects the response of cells (e.g. cancer cells) to drugs. Mimicking these conditions in vitro using patient-derived 3D explants (i.e. tumoroids) provides data with a greater predictive value of drug efficacy in human studies than any other. Our technology allows screening of tumoroids, multicellular spheroids, organoids generated from biopsy tissues and primary cell lines, as well as advanced co-culture models.
Customer-defined Assays
Our platform is highly flexible and provides physiologically relevant 3D models tailored to your needs. We are able to customise many aspects of our assays, such as cell types, assay duration and readouts. By combining your specific knowledge with out expertise, we develop unique disease models to suit your requirements for drug development and evaluation.
High Quality Data
.
We offer a robust, cost-efficient screening service using a miniaturized and medium-throughput ex-vivo platform. Our technology achieves this even when working with extremely limited amounts of tumoroids (e.g. micro explants from human biopsies). This allows us to deliver multiparametric readouts with a high statistical relevance.
